Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Clinical Trials of Antiretroviral Therapy

Coverage provided by Pablo Tebas, M.D.

September 18, 2000

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

  • Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Antiretroviral-Experienced Patients. A Double Blind, Placebo-Controlled Study
    Slide Session 692
    Authored by R. Schooley, R. Myers, P. Ruane, G. Beall, H. Lampiris, M. Miller, R. Mills, I. Mcgowan


Tenofovir disoproxil fumarate belongs to the nucleotide class, whose other member (adefovir) was recently removed -- because of nephrotoxicity -- from the list of drugs under development. Tenofovir has a long half life which permits administration once a day.

In this study, tenofovir was added in doses of 75mg, 150mg and 300mg once a day to patients with detectable viral loads with another (failing) regimen (and with evidence of viral resistance). There were approximately 50 patients for each dose, plus another placebo group. The viral load of the patients receiving tenofovir decreased 0.5-0.7 log copies/mL. Obviously, this is not the situation where anybody wants to test a new drug, but the results were very promising. This drug did not show any evidence of kidney toxicity, a welcomed difference from its cousin adefovir. Currently Gilead is conducting a Phase III trial with tenofovir disoproxil fumarate.


A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
More on HIV Medications
More Research on Tenofovir (Viread)



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement